Retinoblastoma and Neuroblastoma Predisposition and Surveillance.

Junne Kamihara, Franck Bourdeaut, William D Foulkes, Jan J Molenaar, Yaël P Mossé, Akira Nakagawara, Andreu Parareda, Sarah R Scollon, Kami Wolfe Schneider, Alison H Skalet, Lisa J States, Michael F Walsh, Lisa R Diller, Garrett M Brodeur

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 2018;23(13):e98-e106

PMID: 28674118

Abstract

Retinoblastoma (RB) is the most common intraocular malignancy in childhood. Approximately 40% of retinoblastomas are hereditary and due to germline mutations in the gene. Children with hereditary RB are also at risk for developing a midline intracranial tumor, most commonly pineoblastoma. We recommend intensive ocular screening for patients with germline mutations for retinoblastoma as well as neuroimaging for pineoblastoma surveillance. There is an approximately 20% risk of developing second primary cancers among individuals with hereditary RB, higher among those who received radiotherapy for their primary RB tumors. However, there is not yet a clear consensus on what, if any, screening protocol would be most appropriate and effective. Neuroblastoma (NB), an embryonal tumor of the sympathetic nervous system, accounts for 15% of pediatric cancer deaths. Prior studies suggest that about 2% of patients with NB have an underlying genetic predisposition that may have contributed to the development of NB. Germline mutations in and account for most familial NB cases. However, other cancer predisposition syndromes, such as Li-Fraumeni syndrome, RASopathies, and others, may be associated with an increased risk for NB. No established protocols for NB surveillance currently exist. Here, we describe consensus recommendations on hereditary RB and NB from the AACR Childhood Cancer Predisposition Workshop. .

©2017 American Association for Cancer Research.

Address: Dana-Farber Cancer Institute, Boston Children's Hospital, Boston, Massachusetts.; Institut Curie, Integrated Cancer Research Site, Paris, France.; Human Genetics, Medicine and Oncology, McGill University, Montreal, Québec, Canada.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.; Saga Medical Center Koseikan, Saga, Japan.; Sant Joan de Deu, Barcelona Children's Hospital, Barcelona, Catalonia, Spain.; Baylor College of Medicine, Houston, Texas.; Children's Hospital Colorado, Aurora, Colorado.; Casey Eye Institute, Oregon Health and Science University, Portland, Oregon.; Memorial Sloan Kettering Cancer Center, New York, New York.; Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.